phlorhizin has been researched along with Cognitive Dysfunction in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirose, M; Ishida, N; Saito, M; Sanbe, A; Sato, S; Taira, E; Tezuka, Y | 1 |
| Kamdi, SP; Nakhate, KT; Raval, A | 1 |
2 other study(ies) available for phlorhizin and Cognitive Dysfunction
| Article | Year |
|---|---|
Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease.
Topics: Animals; Carotid Artery, Common; Cerebral Small Vessel Diseases; Cerebrovascular Circulation; Cognition; Cognitive Dysfunction; Cytokines; Disease Models, Animal; Glucosides; Hippocampus; Inflammation; Mice; Morris Water Maze Test; Neurons; Phlorhizin; Pyrazoles; Sodium-Glucose Transporter 1 | 2021 |
Phloridzin attenuates lipopolysaccharide-induced cognitive impairment via antioxidant, anti-inflammatory and neuromodulatory activities.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cognitive Dysfunction; Disease Models, Animal; Glutathione; Hippocampus; Lipopolysaccharides; Male; Maze Learning; Memory; Memory Disorders; Mice; Neuroinflammatory Diseases; Neuroprotective Agents; Neurotransmitter Agents; Oxidative Stress; Phlorhizin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2021 |